Novo Nordisk A/S Stock Forecast for 2022 - 2025 - 2030
Updated on 05/27/2022
If the average price target of kr820.00 set by eleven distinguished experts for Novo Nordisk A/S over the past few weeks is reached this year, there would be a potential upside of approximately 25.19% from the last closing price in February, 2022. This potential increase is based on a high estimate of kr1005.00 and a low estimate of kr540.00. If you're thinking of investing in NOVO B stock, it's critical to check out its competitors as well.
25.19% Upside
Novo Nordisk A/S Fair Value Forecast for 2022 - 2025 - 2030
In the past three years, Novo Nordisk A/S's Fair Value has seen a relatively significant increase, rising from kr366.55 to kr477.23. This represents a growth of 30.19%. Analysts predict that Novo Nordisk A/S's Fair Value will increase slightly in the upcoming year, reaching kr516.93. This would represent an increase of 8.32%. Over the next nine years, experts predict that Novo Nordisk A/S's Fair Value will grow at a rate of 108.77%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
12
|
$181.09 | $187.12 | 2.71% | 16 |
| PFE Stock Forecast | Pfizer | Outperform |
3
|
$53.91 | $58.26 | 2.02% | 16 |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£105.80 | £136.08 | 37.87% | 13 |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
14
|
$116.69 | $141.24 | 19.98% | 19 |
| NOVN Stock Forecast | Novartis | Outperform |
0
|
CHF77.22 | CHF103.75 | 19.24% | 12 |
Novo Nordisk A/S Revenue Forecast for 2022 - 2025 - 2030
In the past three years, Novo Nordisk A/S's Revenue has seen a relatively significant increase, rising from kr111.83B to kr140.80B. This represents a growth of 25.9%. Analysts predict that Novo Nordisk A/S's Revenue will increase slightly in the upcoming year, reaching kr151.16B. This would represent an increase of 7.36%. Over the next nine years, experts predict that Novo Nordisk A/S's Revenue will grow at a rate of 79.16%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| SAN Stock Forecast | Sanofi | Outperform |
18
|
103.72€ | 104.66€ | 10.13% | 20 |
| MDT Stock Forecast | Medtronic | Outperform |
18
|
$99.08 | $123.50 | 16.07% | 5 |
| CSL Stock Forecast | CSL | Outperform |
0
|
$266.28 | $228.01 | -14.01% | 10 |
Novo Nordisk A/S Dividend per Share Forecast for 2022 - 2025 - 2030
Novo Nordisk A/S's DPS has seen considerable growth in the last three years, going from kr8.15 to kr10.40 – a gain of 27.61% In the next year, analysts believe that DPS will reach an unimpressive kr11.20 – an increase of 7.71% For the next nine years, the forecast is for DPS to grow by 100.35%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences | Outperform |
11
|
$64.80 | $75.96 | 6.48% | 19 |
| SHW Stock Forecast | Sherwin Williams | Outperform |
15
|
$276.35 | $302.15 | 9.1% | 22 |
| BAYN Stock Forecast | Bayer | Outperform |
16
|
66.58€ | 67.79€ | 14.15% | 14 |
Novo Nordisk A/S Free Cash Flow Forecast for 2022 - 2025 - 2030
Novo Nordisk A/S's Free Cash Flow has seen major growth over the last three years, jumping from kr35.09B to kr48.67B – an increase of 38.68%. In the next year, analysts predict that Free Cash Flow will reach a reasonable kr53.68B – an increase of 10.3%. For the next nine years, the forecast is for Free Cash Flow to grow by 122.37%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BSX Stock Forecast | Boston Scientific | Outperform |
15
|
$41.20 | $49.85 | 21.36% | 23 |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥2.83k | ¥0.00 | 41.37% | 0 |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$76.16 | $89.29 | 18.17% | 3 |
Novo Nordisk A/S Net Income Forecast for 2022 - 2025 - 2030
In three years, Net Income for Novo Nordisk A/S has grown by a respectable 23.63%, going from kr38.63B to kr47.76B. In the coming year, analysts are expecting a small increase in Net Income, predicting it will reach kr50.97B – an increase of 6.72%. Over the next nine years, experts anticipate that Net Income growth for Novo Nordisk A/S will be 89.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| PPG Stock Forecast | PPG Industries | Outperform |
13
|
$130.03 | $156.50 | 21.89% | 20 |
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$206.20 | $287.21 | 10.33% | 24 |
| HZNP Stock Forecast | Horizon Therapeutics Public | Buy |
0
|
$86.60 | $0.00 | 61.66% | 8 |
Novo Nordisk A/S EBITDA Forecast for 2022 - 2025 - 2030
Over the last three years, Novo Nordisk A/S's EBITDA has increased by 24.41%, going from kr51.08B to kr63.55B. In the next year, analysts are expecting a small increase in EPS, predicting it will reach kr67.98B – an increase of 6.97%. The 2030 forecast is for EBITDA to reach kr105.79B or grow by 66.46%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals | Outperform |
7
|
$127.77 | $209.00 | 60.05% | 10 |
| GRF Stock Forecast | Grifols | Outperform |
0
|
16.07€ | 27.25€ | 31.92% | 6 |
| IPN Stock Forecast | Ipsen | Hold |
17
|
96.45€ | 94.86€ | 5.75% | 9 |
Novo Nordisk A/S EBIT Forecast for 2022 - 2025 - 2030
In the past three years, Novo Nordisk A/S's EBIT has seen a tremendous growth rate, increasing from kr47.28B to kr59.34B – an increase of 25.52%. For next year, the 0 analysts predict earnings per share of kr63.62B, which would mean an increase of 7.21%. Over the next nine years, the pros' prediction is EBIT of kr99.92B, which would mean a 9-year growth forecast of 68.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Outperform |
0
|
Rp4.32k | Rp5.47k | 14.56% | 12 |
| SOBI Stock Forecast | Swedish Orphan Biovitrum AB (p... | Outperform |
16
|
kr213.20 | kr210.63 | 20.31% | 6 |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
0
|
$99.99 | $95.80 | -100% | 7 |
Novo Nordisk A/S EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the past three years, Novo Nordisk A/S's EPS has seen a relatively significant increase, rising from kr15.93 to kr20.74. This represents a growth of 30.19%. Analysts predict that Novo Nordisk A/S's EPS will increase slightly in the upcoming year, reaching kr22.47. This would represent an increase of 8.32%. Over the next nine years, experts predict that Novo Nordisk A/S's EPS will grow at a rate of 108.77%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| PRGO Stock Forecast | Perrigo | Outperform |
16
|
$40.33 | $53.30 | 19.02% | 1 |
| APN Stock Forecast | Aspen Pharmacare Holdings | Outperform |
0
|
R203.93 | R193.00 | 20.38% | 0 |
| 4403 Stock Forecast | NOF | Buy |
0
|
¥5.81k | ¥0.00 | 4.99% | 0 |